Noton K Dutta1, Natalie Bruiners2, Matthew D Zimmerman2, Shumin Tan3, Véronique Dartois2, Maria L Gennaro2, Petros C Karakousis1,4. 1. Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 2. Public Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, New Jersey, USA. 3. Tufts University School of Medicine, Department of Molecular Biology and Microbiology, Boston, Massachusetts, USA. 4. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Abstract
BACKGROUND: Tuberculosis (TB) treatment is lengthy and complicated and patients often develop chronic lung disease. Recent attention has focused on host-directed therapies aimed at optimizing immune responses to Mycobacterium tuberculosis (Mtb), as adjunctive treatment given with antitubercular drugs. In addition to their cholesterol-lowering properties, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have broad anti-inflammatory and immunomodulatory activities. METHODS: In the current study, we screened 8 commercially available statins for cytotoxic effect, anti-TB activity, synergy with first-line drugs in macrophages, pharmacokinetics and adjunctive bactericidal activity, and, in 2 different mouse models, as adjunctive therapy to first-line TB drugs. RESULTS: Pravastatin showed the least toxicity in THP-1 and Vero cells. At nontoxic doses, atorvastatin and mevastatin were unable to inhibit Mtb growth in THP-1 cells. Simvastatin, fluvastatin, and pravastatin showed the most favorable therapeutic index and enhanced the antitubercular activity of the first-line drugs isoniazid, rifampin, and pyrazinamide in THP-1 cells. Pravastatin modulated phagosomal maturation characteristics in macrophages, phenocopying macrophage activation, and exhibited potent adjunctive activity in the standard mouse model of TB chemotherapy and in a mouse model of human-like necrotic TB lung granulomas. CONCLUSIONS: These data provide compelling evidence for clinical evaluation of pravastatin as adjunctive, host-directed therapy for TB.
BACKGROUND: Tuberculosis (TB) treatment is lengthy and complicated and patients often develop chronic lung disease. Recent attention has focused on host-directed therapies aimed at optimizing immune responses to Mycobacterium tuberculosis (Mtb), as adjunctive treatment given with antitubercular drugs. In addition to their cholesterol-lowering properties, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have broad anti-inflammatory and immunomodulatory activities. METHODS: In the current study, we screened 8 commercially available statins for cytotoxic effect, anti-TB activity, synergy with first-line drugs in macrophages, pharmacokinetics and adjunctive bactericidal activity, and, in 2 different mouse models, as adjunctive therapy to first-line TB drugs. RESULTS: Pravastatin showed the least toxicity in THP-1 and Vero cells. At nontoxic doses, atorvastatin and mevastatin were unable to inhibit Mtb growth in THP-1 cells. Simvastatin, fluvastatin, and pravastatin showed the most favorable therapeutic index and enhanced the antitubercular activity of the first-line drugs isoniazid, rifampin, and pyrazinamide in THP-1 cells. Pravastatin modulated phagosomal maturation characteristics in macrophages, phenocopying macrophage activation, and exhibited potent adjunctive activity in the standard mouse model of TB chemotherapy and in a mouse model of human-like necrotic TB lung granulomas. CONCLUSIONS: These data provide compelling evidence for clinical evaluation of pravastatin as adjunctive, host-directed therapy for TB.
Authors: Ciaran Skerry; Michael L Pinn; Natalie Bruiners; Richard Pine; Maria L Gennaro; Petros C Karakousis Journal: J Antimicrob Chemother Date: 2014-05-22 Impact factor: 5.790
Authors: Katherine A Mattos; Viviane C G Oliveira; Marcia Berrêdo-Pinho; Julio J Amaral; Luis Caetano M Antunes; Rossana C N Melo; Chyntia C D Acosta; Danielle F Moura; Roberta Olmo; Jun Han; Patricia S Rosa; Patrícia E Almeida; B Brett Finlay; Christoph H Borchers; Euzenir N Sarno; Patricia T Bozza; Georgia C Atella; Maria Cristina V Pessolani Journal: Cell Microbiol Date: 2014-03-21 Impact factor: 3.715
Authors: Ramesh Akkina; Daniel L Barber; Moses T Bility; Karl-Dimiter Bissig; Benjamin J Burwitz; Katrin Eichelberg; Janice J Endsley; J Victor Garcia; Richard Hafner; Petros C Karakousis; Brent E Korba; Rajen Koshy; Chris Lambros; Stephan Menne; Eric L Nuermberger; Alexander Ploss; Brendan K Podell; Larisa Y Poluektova; Brigitte E Sanders-Beer; Selvakumar Subbian; Angela Wahl Journal: Curr HIV Res Date: 2020 Impact factor: 1.581
Authors: Natalie Bruiners; Noton K Dutta; Valentina Guerrini; Hugh Salamon; Ken D Yamaguchi; Petros C Karakousis; Maria L Gennaro Journal: J Lipid Res Date: 2020-08-26 Impact factor: 5.922